Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

NCT05669755 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05669755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 1, 2023
Completion date
October 14, 2027
Enrollment
7,101 (actual)
Sites
633

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease